Clinical Trial

Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways

Study acronym: GITMO-RELAPSE
Recruiting
View on ClinicalTrials.gov →
Summary
This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs/procedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice. The aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-11-16; most recent amendment 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2022-07-18
Trial Details
NCT Number NCT05124288
Lead Sponsor Ciceri Fabio
Collaborators: Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana per la Ricerca sul Cancro
Conditions Acute Myeloid Leukemia, in Relapse
Enrollment 500 participants
Start Date 2022-07-18
Primary Completion 2026-12-20 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2025-05-13